Article Figures & Data
Figures
- Figure 1 Disposition of study participants enrolled in the single ascending dose phase 1 study of VX15/2503
This flow diagram depicts the disposition of the participants in this single-dose, dose-escalation study of intravenously administered VX15/2503. Forty participants were treated with VX15/2503 and 10 with placebo; none discontinued the study. The median infusion time for all patients was 60 minutes, with durations ranging from 45 to 170 minutes.
- Figure 2 Semi-log plot of mean VX15/2503 serum concentrations vs time after a single infusion
Mean serum VX15/2503 concentrations are shown vs scheduled sampling days. Data shown are for antibody-treated patients in each of the 5 dose cohorts; samples from placebo-treated subjects were assayed but not reported because of the absence of antibody in these samples. Sampling times were end of infusion, 4 and 8 hours on days 1 2, 4, 8, 15, 29, 43, 57, 71, 85, 155, and 190; time points beyond day 29 were successively applied to cohorts 2 through 5. Data shown represent mean values ± SD. Serum assays were performed in triplicate using a validated method.15,16
- Figure 3 Mean percent cellular SEMA4D saturation vs time after VX15/2503 administration
Percent VX15/2503 saturation of cSEMA4D on peripheral T lymphocytes is shown for antibody-treated participants in each dose cohort. The scheduled sampling times for each dose cohort were as described in the legend of figure 2. Data shown represent mean values ± SE; flow cytometric assays were performed in triplicate and data analyzed as previously described.16,20 T-cell saturation values below 20% were considered unsaturated; mean predose saturation values ranged between 0.7% and 18%.
Tables
Additional Files
Data Supplement
Files in this Data Supplement:
- Appendix e-1 - Microsoft Word file
Coinvestigators
Files in this Data Supplement:
- Coinvestigators - Microsoft Word file
Related Data
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.